Overall, in vitro analyses demonstrated that the expression of SOX9 is aberrantly silenced by CpG island promoter hypermethylation in bladder cancer, observations especially supported by AZA reactivation analyses. Here, SOX9 is linked to urinary bladder carcinoma.